ADC Therapeutics (ADCT) stock plunged 36% after the company reported data from a Phase 1b study of its drug Zynlonta in combination with Columvi for diffuse large B-cell lymphoma.

Among patients with ER-positive/HER2-negative advanced breast cancer, treatment with camizestrant in combination with Kisqali ...

BNT327, now in early-phase trials, is part of a class of drugs that could one day challenge Keytruda’s dominance. BioNTech ...

Tazeen Ahmad, an analyst from Bank of America Securities, reiterated the Buy rating on Sutro Biopharma (STRO – Research Report). The associated ...

A shorter duration of venetoclax treatment for newly diagnosed acute myeloid leukemia (AML) may enhance efficacy and reduce ...

Initial therapy with sonrotoclax and zanubrutinib showed strong efficacy and acceptable safety in untreated CLL/SLL.

A live biotherapeutic, SER-155 secured FDA fast track status in December 2023. SER-155 also supports the decrease of ...

Regeneron (REGN) announced new and updated data for odronextamab were presented at the 66th American Society of Hematology, or ASH, annual ...

Implementing an individualized starting dose (ISD) of niraparib (Zejula; GSK) reduced severe hematologic adverse event (AE) ...

SAN DIEGO -- A fixed-duration oral combination significantly reduced the risk of disease progression or death compared with ...

Patients with newly diagnosed multiple myeloma experienced robust clinical activity when treated with Tecvayli (teclistamab) ...